PPARγ agonist pioglitazone reverses pulmonary hypertension and prevents right heart failure via fatty acid oxidation
Ekaterina Legchenko, Philippe Chouvarine, Paul Borchert et al. · Science Translational Medicine · 2018
) in primary cardiomyocytes. We recapitulated our major pathogenic findings in human end-stage PAH: (i) in the pressure-overloaded failing RV (miR-197 and miR-146b up-regulated), (ii) in peripheral pulmonary arteries (miR-146b up-regulated, miR-133b down-regulated), and (iii) in plexiform vasculopathy (miR-133b up-regulated, miR-146b down-regulated). Together, PPARγ activation can normalize epigenetic and transcriptional regulation primarily related to disturbed lipid metabolism and mitochondrial morphology/function in the failing RV and the hypertensive pulmonary vasculature, representing a therapeutic approach for PAH and other cardiovascular/pulmonary diseases.
Cited by 295 works. doi:10.1126/scitranslmed.aao0303
Authors
- Ekaterina Legchenko
- Philippe Chouvarine
- Paul Borchert
- Angeles Fernandez‐Gonzalez
- Erin R. Snay
- Martin Meier
- Lavinia Maegel
- S. Alex Mitsialis
- Eva A. Rog‐Zielinska
- Stella Kourembanas
- Danny David Jonigk
- Georg Hansmann
References
- 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
- Independent filtering increases detection power for high-throughput experiments
- Reversal of experimental pulmonary hypertension by PDGF inhibition
- Pioglitazone after Ischemic Stroke or Transient Ischemic Attack
- Right heart dysfunction in heart failure with preserved ejection fraction
- Statistical significance of quantitative PCR
- MicroRNA-34a regulates cardiac ageing and function
- Transverse aortic constriction leads to accelerated heart failure in mice lacking PPAR-γ coactivator 1α
- Gene Expression Patterns in the Lungs of Patients With Primary Pulmonary Hypertension
- Formation of Plexiform Lesions in Experimental Severe Pulmonary Arterial Hypertension